2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林召开，作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学专家参与，为全球学者提供了良好的交流平台。目前，ESMO官网已公布了大会部分口头报告及壁报标题，肿瘤瞭望特将目前乳腺癌领域入选的中国学者投稿研究进行汇总，并诚邀您持续关注重磅研究进展！
编者按：2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林召开，作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学专家参与，为全球学者提供了良好的交流平台。目前，ESMO官网已公布了大会部分口头报告及壁报标题，肿瘤瞭望特将目前乳腺癌领域入选的中国学者投稿研究进行汇总，并诚邀您持续关注重磅研究进展！
Breast cancer，early（早期乳腺癌）
Mini oral session
297MO-Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain:A Prospective，Randomized Phase 3 Trial
培非格司亭给药时机与培非格司亭诱导的骨痛：一项前瞻性随机III期试验
讲者：Peiyong Li(Guangzhou，China)
Posters and ePosters
298P-Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in Asian population with HER2-positive breast cancer
用于预测亚洲HER2阳性乳腺癌患者复发和生存风险的新型HER2RI检测方法的开发和验证
讲者：Yi-Kun Kang(Beijing，China)
300P-TIME-HER:A Dynamic Predictive Model for Prognosis of HER2-Positive Early Breast Cancer after HER2-targeted Therapy
TIME-HER：HER2靶向治疗后HER2阳性早期乳腺癌预后的动态预测模型
讲者：Qingyao Shang(Beijing，China)
305P-Neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer:three-year outcomes from the MUKDEN 01 study
MUKDEN 01研究三年随访结果：吡咯替尼联合来曲唑及达尔西利新辅助治疗三阳性乳腺癌的疗效分析
讲者：刘彩刚(Shenyang，China)
306P-Neoadjuvant SHR-A1811 with or without pyrotinib in HER2-positive breast cancer(MUKDEN 07):A multi-cohort，multicenter，phase II clinical trial
MUKDEN 07研究：一项针对HER2阳性乳腺癌的多队列、多中心Ⅱ期临床试验，评估新辅助治疗中SHR-A1811联合或不联合吡咯替尼的疗效
讲者：刘彩刚(Shenyang，China)
312P-Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c，lymph node-negative，and hormone receptor-negative breast cancer:a study based on the SEER database and a Chinese cohort
T1c期、淋巴结阴性且激素受体阴性乳腺癌患者新辅助治疗与辅助治疗生存结局的对比研究：基于SEER数据库与中国队列的分析
讲者：Shiyu Liang(Chengdu，China)
317P-Myeloprotection with Trilaciclib in Hormone Receptor(HR)-Negative early breast cancer receiving adjuvant therapy
Trilaciclib在激素受体（HR）阴性早期乳腺癌辅助治疗中的骨髓保护作用
讲者：Jiajia Huang(Guangzhou，China)
344P-Inadequate ovarian suppression in young premenopausal women with estrogen receptor-positive breast cancer on ovarian suppression therapy
接受卵巢功能抑制治疗的年轻绝经前雌激素受体阳性乳腺癌患者卵巢抑制不充分的现象
讲者：Dar-Ren Chen(Changhua City，Taiwan)
348P-Ten-Year Outcomes of Epirubicin Plus Paclitaxel Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel in Hormone Receptor–Positive，ERBB2-Negative，Node-Positive Breast Cancer:A Phase 3 Randomized Clinical Trial
表柔比星联合紫杉醇对比表柔比星联合环磷酰胺序贯紫杉醇治疗激素受体阳性、ERBB2阴性、淋巴结阳性乳腺癌的10年随访结局比较：一项3期随机临床试验
讲者：Liuliu Quan(Beijing，China)
382P-A modern DCIS-IBC guide board for postoperative upgrading in ductal carcinoma in situ
导管原位癌术后升级为浸润性乳腺癌的现代风险评估指南框架
讲者：Chenglong Duan(xian，China)
383P-Spatial transcriptomics reveals biological disparities in ipsilateral breast tumor recurrence after breast-conserving surgery
空间转录组学揭示保乳术后同侧乳腺肿瘤复发的生物学差异
讲者：FEILIN QU(Shanghai，China)
385P-Is axillary intervention necessary for selected patients with cN0-1 breast cancer after neoadjuvant chemotherapy?
新辅助化疗后的cN0-1乳腺癌患者是否有必要进行腋窝干预？
讲者：Yuhan Zhang(Xi’an，Shaanxi Province，China)
386P-The Innovative Lancet Technique for Breast-Conserving Oncoplastic Surgery in Small-to Medium-Sized Breasts with Tumors in the Lower Inner Quadrant:A Multicenter Retrospective Study(IOS Study)
针对中小乳房下内侧象限肿瘤的保乳整形手术创新Lancet技术：一项多中心回顾性研究（IOS研究）
讲者：Rui Zhuo(Guilin，China)
389P-A Competing Risk Analysis Model to Explore the Impact of Postoperative Radiotherapy for Sentinel Lymph Node Micrometastases or ITCs in Female Breast Cancer
竞争风险分析模型探讨术后放疗对女性乳腺癌前哨淋巴结微转移或孤立肿瘤细胞（ITCs）的影响
讲者：Yudong Zhou(xian，China)
391P-Application of Preoperative 3-dimensional Vascular Reconstruction Assessment in Preventing Ischemic Complications After Nipple-Sparing Mastectomy:A Randomized Controlled Trial
术前三维血管重建评估在预防保留乳头乳房切除术后缺血性并发症中的应用：一项随机对照试验
讲者：Xiaoqi Zhang(Guangzhou，China)
398P-Patient-reported outcomes(PROs)with GnRHa as ovarian function suppression(OFS)treatment in pre-menopausal Chinese patients with hormone receptor-positive(HR+)early breast cancer(EBC):a real-world observational investigation
GnRHa作为卵巢功能抑制（OFS）治疗绝经前激素受体阳性（HR+）早期乳腺癌（EBC）患者的患者报告结局（PROs）：一项真实世界观察性研究
讲者：Xiyu Liu(Shanghai，China)
403P-Axillary Lymph Node Dissection Offers No Survival Benefit in Breast Cancer Patients with Sentinel Lymph Node Micrometastases After Neoadjuvant Therapy
腋窝淋巴结清扫术对新辅助治疗后前哨淋巴结微转移的乳腺癌患者无生存获益
讲者：Jianing Zhang(Xi’an，China)
414P-Prognostic Value of ER reduction rate between pre-and post-Neoadjuvant Chemotherapy in Patients with ER-Positive/HER2-Negative Breast Cancer
新辅助化疗前后ER降低率对ER阳性/HER2阴性乳腺癌患者的预后价值
讲者：Shunyi Liu(Fuzhou，China)
416P-Diverse adjuvant treatment in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy:A single center real-world study
新辅助化疗后残留病灶的三阴性乳腺癌患者的多样化辅助治疗：一项单中心真实世界研究
讲者：Xi Chen(Beijing，China)
417P-Proteomic analysis of residual disease identifies potential prognostic biomarkers of triple-negative breast cancer after neoadjuvant chemotherapy
三阴性乳腺癌新辅助化疗后残留病灶的蛋白质组学分析确定潜在的预后生物标志物
讲者：Xi Chen(Beijing，China)
418P-Impact of BRCAness Status on Prognosis and Chemotherapy Sensitivity in Non-pCR Triple-Negative Breast Cancer Patients After Neoadjuvant Treatment
BRCA样状态对新辅助治疗后未达病理完全缓解（non-pCR）三阴性乳腺癌患者预后及化疗敏感性的影响
讲者：Hangcheng Xu(Beijing，China)
429eP-Identification of Low Risk Patients with ER+/HER2-Breast Cancer by mRNA-based LRP Model
通过基于mRNA的LRP模型识别ER+/HER2-乳腺癌的低危患者
讲者：梁旭(Beijing，China)
430eP-Peri-lymph node tattooing with carbon nanoparticles suspension:a novel strategy for targeted axillary dissection in breast cancer
纳米碳混悬标记淋巴结周围：一种乳腺癌靶向腋窝清扫的创新策略
讲者：Junyuan Lv(Zunyi，China)
436eP-ABCB1 gene polymorphism and effectiveness of olanzapine-containing antiemetic prophylaxis for patients receiving adriamycin and cyclophosphamide chemotherapy
ABCB1基因多态性与接受阿霉素和环磷酰胺化疗患者含奥氮平止吐预防的有效性
讲者：Winnie Yeo(Hong Kong，Hong Kong SAR，China)
444eP-Impact of Typical Somatic Gene Mutation Characteristics on Homologous Recombination Deficiency in Breast Cancer
典型体细胞基因突变特征对乳腺癌同源重组缺陷的影响
讲者：Jinsui Du(Xi’an，Shaanxi Province，China)
448eP-KBD111 is a highly selective，long-acting and brain-penetrant PARP1 inhibitor
KBD111是一种高选择性、长效、能穿透血脑屏障的PARP1抑制剂
讲者：Yang Chen(chengdu，China)
461eTiP-EXTEND:Neoadjuvant Trastuzumab Deruxtecan(T-DXd)versus Standard Treatment for Medium-risk human epidermal growth factor receptor 2(HER2)–positive Early Breast Cancer
EXTEND研究：对比新辅助治疗中德曲妥珠单抗（T-DXd）与标准方案用于中危HER2阳性早期乳腺癌的疗效
讲者：李俊杰(Shanghai，China)
Breast cancer，locally advanced（局部晚期乳腺癌）
Posters and ePosters
466P-Efficacy and Safety of JS105，a Selective Inhibitor of Mutant PI3Kα，in Patients with Advanced Cancer
选择性突变型PI3Kα抑制剂JS105在晚期癌症患者中的疗效与安全性研究
讲者：闫敏(Zhengzhou，China)
468P-The Clinical Significance and Prognostic Impact of stromal tumor infiltrating lymphocytes in HER2-Positive Breast Cancer:Including a Neoadjuvant Subgroup Analysis
HER2阳性乳腺癌间质肿瘤浸润淋巴细胞的临床意义和预后影响：包括新辅助治疗亚组分析
讲者：Yujing Chang(Chengdu，China)
470P-Neoadjuvant cadonilimab(anti-PD-1/CTLA-4 bispecific antibody)plus chemotherapy in early or locally advanced triple-negative breast cancer:supplementary biomarker analyses from CABIN trial
新辅助cadonilimab（抗pd-1/CTLA-4双特异性抗体）联合化疗治疗早期或局部晚期三阴性乳腺癌：来自CABIN试验的补充生物标志物分析
讲者：TAO WU(Changde City，China)
472P-The mechanism and preclinical translational research of targeted inhibition of ATM enhancing the therapeutic efficacy of PD-1/PD-L1 inhibitors in triple-negative breast cancer by modulating CD8?T cells in the tumor immune microenvironment
靶向抑制ATM通过调控肿瘤免疫微环境中CD8?T细胞增强PD-1/PD-L1抑制剂治疗三阴性乳腺癌的机制及临床前转化研究
讲者：Xiaojing Guo(Tianjin，China)
473P-Neoadjuvant Trilaciclib plus chemotherapy and anti-PD1-antibody for locally advanced triple-negative breast cancer:Preliminary short-term efficacy and safety results from a single-arm，multicenter，phase II trial
新辅助治疗中Trilaciclib联合化疗及抗PD-1抗体治疗局部晚期三阴性乳腺癌：一项单臂、多中心Ⅱ期试验的初步短期疗效与安全性结果
讲者：Jiaxuan Liu(Beijing，China)
479P-H4K8la/CXCL10-driven M2 polarization via tumor cell-macrophage lactate feedback loop mediates doxorubicin resistance in TNBC
H4K8la/CXCL10通过肿瘤细胞-巨噬细胞乳酸反馈回路驱动M2型巨噬细胞极化，介导三阴性乳腺癌对多柔比星的耐药性
讲者：Qingqing Wang(Wuhan，China)
京公网安备 11010502033352号